Ceva Merges R&D Activity
FRANCE - Ceva Santé Animale has appointed Dr Steve Chu to its executive committee with responsibility for all R&D activities.
5 September 2014
2 minute read
By: 
The move recognises the growing importance of biotechnology and the resulting convergence of pharmaceutical and biological research.
Dr Chu joined Ceva in 2011 and has an outstanding record throughout his 30 year career in veterinary research, where he previously held senior research positions with Fort Dodge, Elanco and Pfizer animal health.
He is known throughout the industry for his work in developing several first-of–its kind novel animal vaccines and received the CDC Director’s Innovation Award for his contribution to the development of an Equine West Nile virus vaccine.
He will remain based in the US and add responsibility for global pharmaceutical research to his current role, where he successfully led Ceva’s biology R&D.
The nomination of Dr Chu will place an accent on speed of scientific innovation and a first-hand knowledge of the US and Chinese markets at the centre of the Ceva board.
